Macroaxis: Personalized Investing
Simple Personalized Investing

GILD AMGN BIIB CELG Consumption Advertising Market Drivers Wireless 
Benchmark SP 500  1,650   0.91  Index Moved Down -0.06% ...


Processing
Collecting data for SGMO

Sangamo quote and profile

 
 Companies |  Insiders  | Dashboard  
     
7.98
  
STOCK
0.05  Macroaxis: 0.63 Up   0.63%  
Year To Date
4.0111.24
Last 1 Month(s)
7.8110.65
Trading Day 
7.778.18
May 25 2013 

Diversification Suggestion

Use Sangamo to enhance returns of your portfolios. The stock experiences moderate upward volatility
Analyze Sangamo Biosciences Trend or Check current 30 days Sangamo correlation with market (S&P 500)
1 Month Beta -0.4  
Highest Price:  
Lowest Price:  
10.65  
7.81  
April 25 2013 
May 22 2013 
As returns on market increase, returns on owning Sangamo are expected to decrease at a much smaller rate. During bear market, Sangamo is likely to outperform the market.
Sangamo Biosciences Inc Almost negative betaSangamo Biosciences Beta Legend
SGMO United States Nasdaq
Sangamo Biosciences Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.sangamo.com
Contact Number: 510. 970. 6000
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation496.66 M
Shares Outstanding53.35 M
Number of Shares Shorted7.25 M
Revenue21.66 M
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 thisGreen SGMO SGMO agains markets  0.63 % Macroaxis: 0.63 Moved Up  
 
 United States Russel   0.00 % No Change  
 United States SP 500   0.06 % Macroaxis: 0.06 Moved Down  
 
 United States NYSE   0.25 % Macroaxis: 0.25 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Sangamo Leadership

Edward Lanphier President CEO, Director
Edward II Founder, CEO and President and Director
William Ringo Independent Chairman of the Board, MBA
Dale Ando Vice President - Therapeutic Development, Chief Medical Officer

Sangamo Price and Market Media

The median price of Sangamo for the period between Thu, Apr 25, 2013 and Sat, May 25, 2013 is 8.52 with a coefficient of variation of 10.69. The daily time series for the period is distributed with a sample standard deviation of 0.94, arithmetic mean of 8.78, and mean deviation of 0.76. The Stock received substential amount of media coverage during this period.
Sangamo         SP 500
Price Growth (%)
 
1
Sangamo BioSciences Announces Presentation At The Needham He...04/26/2013Macroaxis: News
2
SANGAMO BIOSCIENCES INC. Sangamo BioSciences Announces First...05/02/2013Macroaxis: News
3
SANGAMO BIOSCIENCES INC. Sangamo BioSciences Presents Clinic...05/16/2013Macroaxis: News
4
SANGAMO BIOSCIENCES INC. Sangamo BioSciences Presents New Da...05/21/2013Macroaxis: News

Sangamo Summary

Sangamo Biosciences Inc [SGMO] is traded on NASDAQ in USA. It is located in Richmond, CA and employs 84 people. The company currently falls under 'Small-Cap' category with current market capitalization of 512.19 M. Sangamo Biosciences Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 53.35 M outstanding shares of which 7.25 M shares are at this time shorted by private and institutional investors with about 13.8 trading days to cover.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNAbinding proteins for gene regulation and gene modification in the United States. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
More
Than
88 %
 
Follow Sangamo with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Sangamo to your reader
 

Sangamo Research Report

Sangamo vs. Gilead

Correlation analysis and fundamentals comparison between Sangamo Biosciences and Gilead Sciences

Sangamo Executives

Ward Wolff CFO, Principal Accounting Officer and Executive VP

Sangamo Directors

John Larson Independent Director
Steven Mento Independent Director
Stephen Dilly Independent Director, Ph.D
Thomas Wiggans Independent Director, MBA
Paul Cleveland Independent Director

Sangamo Fundamentals

Total Asset vs Number of Employees
Gross Profit vs Earnings Per Share
Total Asset vs Current Ratio
Revenue vs Earnings Per Share

Sangamo vs Competition

Sangamo vs. Gilead Sciences Inc
Sangamo vs. Amgen Inc
Sangamo vs. Biogen Idec Inc
Sangamo vs. Celgene Corporation
Sangamo vs. Regeneron Pharmaceuticals Inc
Sangamo vs. Alexion Pharmaceuticals Inc
Sangamo vs. Vertex Pharmaceuticals Incorporated
Sangamo vs. BioMarin Pharmaceutical Inc
Sangamo vs. Illumina Inc
Sangamo vs. Onyx Pharmaceuticals Inc

Sangamo May 25 2013 Opportunity Range

Downside Deviation4.55
Information Ratio(0.36)
Maximum Drawdown14.51
Value At Risk(7.17)
Potential Upside3.3

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium